Increased Upper and Lower Tract Urothelial Carcinoma in Patients with End-Stage Renal Disease: A Nationwide Cohort Study in Taiwan during 1997–2008

Shuo-Meng Wang, Ming-Nan Lai, Pau-Chung Chen, Yeong-Shiau Pu, Ming-Kuen Lai, Jing-Shiang Hwang, and Jung-Der Wang

1 Department of Urology, National Taiwan University Hospital, Taipei 10002, Taiwan
2 Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University, Taipei 10020, Taiwan
3 Department of Statistics, Feng Chia University, Taichung 40724, Taiwan
4 Chang Gung Memorial Hospital, Taipei 10507, Taiwan
5 Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan
6 Department of Public Health, National Cheng Kung University Medical College, Tainan City 70101, Taiwan
7 Department of Internal Medicine and Occupational and Environmental Medicine, National Cheng Kung University Hospital, Tainan City 70403, Taiwan

Correspondence should be addressed to Jung-Der Wang; jdwang121@gmail.com

Received 23 February 2014; Accepted 15 May 2014; Published 16 June 2014

Academic Editor: Li-Jen Wang

Copyright © 2014 Shuo-Meng Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Urothelial cancer (UC) is the leading cancer of patients with end-stage renal disease (ESRD) in Taiwan. The aims of this study were to explore the time trends of UC incidences and propose possible etiologic factors.

Methods. Abstracting from the National Health Insurance Research Database (NHIRD), there were 90,477 newly diagnosed cases of ESRD between 1997 and 2008 covering the patients aged 40–85. Among them, 2,708 had developed UC after diagnosis of ESRD. The CIR_{40−85} (cumulative incidence rate) of upper tract UC (UTUC) and lower tract UC (LTUC) were calculated for ESRD patients and general population, as well as SIR_{40−85} (standardized incidence ratio) for comparison. Results. Female ESRD patients were found to have 9–18 times of elevated risks of UC, while those of males were increased up to 4–14 times. The time trends of CIR_{40−85} and SIR_{40−85} of UTUC in females appear to decline after calendar year 2000. These trends may be related to AA associated herbal products after 1998. Conclusions. Patients with ESRD are at increased risks for both LTUC and UTUC in Taiwan. We hypothesize that the time trends associate with the consumption of aristolochic acid in Chinese herbal products (female predominant).

1. Introduction

Various studies carried out in different regions around the world have found that the incidence of malignancy is generally higher in patients suffering from end-stage renal disease (ESRD) [1–4]. Compared with other countries, Taiwan has a remarkably high incidence and prevalence of patients with ESRD [5, 6]. In Taiwan, bladder, liver, and kidney cancers are leading malignancies in patients with chronic dialysis in a 12-year cross-sectional study between 1997 and 2008. Standardized incidence ratios (SIR) of upper tract urinary cancer (UTUC) decline yearly after first dialysis. However, lower urinary tract urothelial cancer (LTUC) persists high in SIR years after first dialysis [7]. However, this study did not explore the possible etiology for the increased risks nor did it stratify for UTUC and renal cell carcinoma.

Among the possible causes for the urothelial cancer, cigarette smoking is among the top candidates associated with increased bladder [8]. Since aristolochic acid (AA) has been documented to be both nephrotoxic and carcinogenic [9, 10], AA-containing CHPs (Chinese herbal products) were banned in November 2003 in Taiwan. However, the effect...
of banning licensed AA-containing CHPs has never been systematically evaluated.

This study is conducted to determine the cumulative incidence rates (CIR) and SIR in different calendar years for LTUC and UTUC to elucidate the time trends and, furthermore, to preliminarily explore their possible etiologies including tobacco smoking and prescription frequency of AA-containing CHPs. The registry of catastrophic illnesses in Taiwan National Health Insurance and the reimbursement database provides us an excellent opportunity to explore the hypothesis.

2. Methods

This study was approved by the Ethics Review Board of the National Taiwan University Hospital before commencement. In addition, the study complies with personal data protection regulations (Data Protection Act).

2.1. Study Population. In this study, the selected subjects registered under catastrophic illnesses from the NHIRD cover the period of 1997–2008. Data on patient demographics (gender and date of birth), diagnoses and treatment (the date treatment began and the date of death or transplantation), and follow-up duration between January 1997 and December 2008 were retrieved. We allowed two months (up to the end of February of 1997) to exclude prevalent cases of ESRD from the above retrieved NHIRD data. Enrolled incident cases included those coded with the following international classification of disease 9th revision (ICD-9) codes: bladder cancer (ICD-9 code 188), renal pelvis and ureter (ICD-9 codes 189.1 and 189.2, resp.), and ESRD (ICD code 585). NHI database enrollees, namely, general population of Taiwan, were taken as the reference group after excluding all the patients with ESRD. Since the age band of urothelial cancer (UC) developed cases falls between 40 and 84, we enrolled patients within this category to calculate SIR40–84 and CIR40–84. The entire procedure for the inclusion of the subjects (aged between 40 and 84) is illustrated in Figure 1.

2.2. Statistical Analysis. The study interval is defined from January 1997 to December 31, 2008 since registration system is more comprehensive after early 1997. Follow-up time is calculated as person-year at risk beginning with the date of registered ESRD and ending at situation of death, transplantation, or diagnosis of urinary tract cancer depending on which one comes first. Since all ESRD patients are waived from any copayment in our National Health Insurance (NHI), none (or, extremely rare) would abandon such an important benefit except the deceased. Incidence rates were calculated per 100,000 person-years at risk of UC stratified by age and sex. The age stratified incidence rates for UC in the reference population were used to calculate the number of expected cases under the assumption that the reference population would share the same cancer experience as patients with ESRD for each age stratum. The total number of observed UC cases summed up across all age strata divided by that of expected cases was then defined as the standardized incidence ratio (SIR). We then calculated the 95% confidence intervals (95% CIs) under the assumption of Poisson distribution. The cumulative incidence rate (CIR) formula was calculated as follows: $CIR = 1 - \exp[-\sum_{i} IR_i (\Delta t_i)]$, where $IR_i$ represents the age-specific incidence rate and $\Delta t_i$ indicates the range of each age stratum. We calculated the CIR40–84, which could be interpreted as the cumulative risk of developing UC for an average ESRD patient, if he or she had lived from the age of 40 to 84. All of the above analyses were carried out using the SAS software package, Version 9.1 (SAS Institute Inc., Cary, NC).

We examine the trend of CIR and SIR in every 6-year period from 1998 to 2008 by fitting a simple linear regression model: $\log(Y_t) = \alpha + \beta t + \epsilon_t$, where $t = 1, 2, \ldots, 6$ and $Y_t$ is the $t$th CIR or SIR of the examined period [11]. The coefficient $\beta$ determines strength of the trend and the direction of increase or decrease in that period.

3. Results

A total of 103,527 newly diagnosed ESRD patients were identified between March 1997 and December 2008. After excluding those who accepted kidney transplantation and those with incomplete patient information, we obtained a total of 90,447 ESRD cases and 419,884 person-years at risk. Within the age group of 40–84, there were approximately 7 million people registered in the NHIC system during the period of 1997–2008 (as summarized in Figure 1). After 12 years of follow-up, there were 41,115 UC developed from the general population with an approximate 100 million person-years at risk accumulated. A total of 2,214 cases were excluded from the ESRD cohort because the diagnosis of UC was ahead of that of ESRD, leaving 2,708 new UC cases developed after the diagnosis of ESRD. Development of UTUC and LTUC is persistent after first dialysis. And age is a specific factor in both genders and UTUC and LTUC. About 93.4% of upper tract and 97.4% of lower tract patients were provided with histopathologic reports, which are taken from either biopsy or surgical pathology specimen.

According to the demographic characteristics of ESRD patients, which are summarized in Table 1, there are 1,481 cases of LTUC and 1,227 cases of UTUC enrolled. The SIR40–84 of urothelial cancer is summarized in Table 2, which shows an increased trend for all types of UC after 1997 and becomes stabilized after 2004 for both male and female. The female SIRs of different calendar years are generally higher than those of males, of which the SIRs of UTUC are the highest among all UC.

The age-sex specific incidence rates and CIR40–84 for all types of UC are summarized in Table 3, which shows that both upper and lower UC occurred in both genders and such trends begin with young age groups. It also shows that the CIR40–84 of females are generally higher than those of males in all types of UC for the same time periods with an exception of LTUC in 1997–99. Similar to the SIR40–84, CIR40–84 of both genders seems to show an increased trend during the 12 years of follow-up and slightly decreased in the last 3 years, especially for UTUC. As the CIR40–84 of
4. Discussion

Quite different from studies of western countries, we have found that females seem more vulnerable to develop upper or lower location of urothelial cancer after diagnosis of end-stage renal disease, especially in UTUC (Table 1). In fact, female ESRD patients were found to have 9–16 and 11–18 times of elevated risks of LTUC and UTUC, while those of males were increased up to 4–8 and 7–14 times, as summarized in Table 2. The trend of female majority is further corroborated by the estimation of CIR_{40–84} (Table 3). The CIR_{40–84} estimates the probability that in Taiwan an average person with ESRD would develop the event (namely, UTUC or LTUC) if he/she lived up to the age of 85, while the SIR_{40–84} is the total number of observed UC cases summed up across all age strata divided by the total number of expected cases. Moreover, we have found a consistently increasing
**Table 1:** Characteristics of patients with end-stage renal disease between 40 and 84 years old under maintenance dialysis in the registry of catastrophic illnesses between March 1997 and December 2008.

|                      | Male    | Female  |
|----------------------|---------|---------|
| Number of the subjects with ESRD | 43,937  | 46,496  |
| Total person-years at risk     | 197,753 | 222,131 |
| Age at start of dialysis (total person-years) |         |         |
| <40 years               | 35,307  | 26,653  |
| 40–49 years             | 35,821  | 41,327  |
| 50–59 years             | 50,873  | 50,373  |
| 60–69 years             | 56,140  | 66,570  |
| 70–84 years             | 54,919  | 63,861  |
| Duration of follow-up years: number (%) |         |         |
| <1 year                 | 10,575 (24.1) | 10,313 (22.1) |
| ≥1 and <5 years         | 19,426 (44.2) | 19,701 (42.4) |
| ≥5 and <10 years        | 11,543 (26.3) | 13,415 (28.9) |
| ≥10 years               | 2393 (5.4)  | 3067 (6.6) |
| Urothelial cancer cases |         |         |
| Lower tract urothelial cancer: number (%) | 634 (42.8) | 847 (57.2) |
| Upper tract urothelial cancer: number (%)   | 417 (34.0) | 810 (66.0) |

**Table 2:** Age-standardized incidence rates (ages between 40 and 84) for patients under maintenance dialysis stratified by sex and calendar year.

|       | LTUC | UTUC |
|-------|------|------|
|       | SIR<sub>40-84</sub> (95 %CI) | SIR<sub>40-84</sub> (95 %CI) |
| **Male** |      |      |
| 1998   | 16/2.7 | 5.9 (3.6–9.7) | 7/0.5 | 13.0 (6.2–27.3) |
| 1999   | 27/6.0 | 4.5 (3.0–6.6) | 18/1.3 | 13.9 (8.8–22.1) |
| 2000   | 48/5.7 | 8.4 (6.4–11.2) | 19/1.6 | 12.2 (7.8–19.1) |
| 2001   | 43/6.8 | 6.3 (4.7–8.5) | 28/2.2 | 12.9 (8.9–18.7) |
| 2002   | 68/8.4 | 8.1 (6.4–10.3) | 34/2.9 | 11.9 (8.5–16.6) |
| 2003   | 65/10.5 | 6.2 (4.8–7.9) | 49/3.5 | 13.9 (10.5–18.4) |
| 2004   | 63/12.5 | 5.1 (4.0–6.5) | 53/4.1 | 12.8 (9.8–16.8) |
| 2005   | 61/13.7 | 4.5 (3.5–5.8) | 35/4.9 | 11.9 (8.5–16.6) |
| 2006   | 74/14.0 | 5.3 (4.2–6.6) | 52/5.5 | 9.4 (7.2–12.3) |
| 2007   | 79/14.7 | 5.4 (4.3–6.7) | 58/6.1 | 9.5 (7.3–12.3) |
| 2008   | 83/16.6 | 5.0 (4.0–6.2) | 65/5.8 | 11.2 (8.8–14.2) |
| **Female** |      |      |
| 1998   | 12/1.3 | 9.0 (5.1–15.8) | 11/0.8 | 14.3 (7.9–25.8) |
| 1999   | 29/3.1 | 9.5 (6.6–13.7) | 20/1.8 | 10.9 (7.1–16.9) |
| 2000   | 36/3.3 | 10.8 (7.8–14.9) | 47/2.7 | 17.7 (13.3–23.6) |
| 2001   | 49/3.9 | 12.6 (9.5–16.6) | 56/3.1 | 18.4 (14.1–23.9) |
| 2002   | 76/5.1 | 14.8 (11.8–18.5) | 57/4.1 | 13.9 (10.7–18.0) |
| 2003   | 83/5.5 | 15.1 (12.1–18.7) | 83/5.0 | 16.5 (13.3–20.4) |
| 2004   | 89/6.7 | 13.3 (10.8–16.4) | 94/5.7 | 16.6 (13.5–20.3) |
| 2005   | 118/7.3 | 16.1 (13.5–19.3) | 93/6.8 | 13.7 (11.2–16.8) |
| 2006   | 136/8.3 | 16.4 (13.9–19.5) | 113/7.8 | 14.5 (12.1–17.4) |
| 2007   | 121/7.4 | 16.3 (13.7–19.5) | 107/7.9 | 13.5 (11.2–16.3) |
| 2008   | 100/8.3 | 12.0 (9.9–14.6) | 116/8.5 | 13.6 (11.4–16.4) |

LTUC: lower urinary tract urothelial cancer; UTUC: upper urinary tract urothelial cancer; and SIR: standard incidence rate.
Table 3: Sex- and age-specific rates (per 100,000 person-years) and cumulative incidence rates up to 84 years old (CIR<sub>40–84</sub>) of urothelial cancer calculated for every 3-year interval between 1997 and 2008.

| Age category | LTUC Male | UTUC Male | LTUC Female | UTUC Female |
|--------------|-----------|-----------|-------------|-------------|
| 1997–99      |           |           |             |             |
| 40–49        | 372.0     | 148.8     | 361.9       | 180.9       |
| 50–59        | 491.3     | 109.2     | 600.0       | 250.0       |
| 60–69        | 774.9     | 122.3     | 771.1       | 175.3       |
| 70–84        | 952.8     | 129.9     | 504.5       | 232.8       |
| CIR<sub>40–84</sub> | 0.3       | 0.1       | 0.2         | 0.1         |
| 2000–02      |           |           |             |             |
| 40–49        | 400.1     | 100.0     | 700.1       | 140.0       |
| 50–59        | 1013.8    | 362.1     | 999.5       | 309.4       |
| 60–69        | 1027.3    | 296.3     | 1059.3      | 554.1       |
| 70–84        | 1103.5    | 120.4     | 948.5       | 210.8       |
| CIR<sub>40–84</sub> | 0.3       | 0.1       | 0.3         | 0.1         |
| 2003–05      |           |           |             |             |
| 40–49        | 327.9     | 131.2     | 526.6       | 292.6       |
| 50–59        | 832.1     | 282.3     | 1125.7      | 616.8       |
| 60–69        | 701.8     | 259.9     | 1158.0      | 496.3       |
| 70–84        | 1035.8    | 172.6     | 1140.5      | 245.2       |
| CIR<sub>40–84</sub> | 0.3       | 0.1       | 0.4         | 0.2         |
| 2006–08      |           |           |             |             |
| 40–49        | 274.7     | 85.9      | 511.0       | 148.4       |
| 50–59        | 639.4     | 108.4     | 1366.9      | 431.7       |
| 60–69        | 810.8     | 170.7     | 1018.6      | 392.5       |
| 70–84        | 840.4     | 166.1     | 992.6       | 215.1       |
| CIR<sub>40–84</sub> | 0.3       | 0.1       | 0.4         | 0.1         |

LTUC: lower urinary tract urothelial cancer; UTUC: upper urinary tract urothelial cancer; and CIR: cumulative incidence rate.

The trend of SIR<sub>40–84</sub> (Table 2) and CIR<sub>40–84</sub> (Table 3) of UTUC in ESRD before 2003 and it stabilized or slightly dropped after 2003–05 based on a nationwide data for both males and females. The CIR<sub>40–84</sub> of LTUC among females were initially lower than those of males before 2000, and they became higher than those of males after 2000 (Table 3). And the SIR<sub>40–84</sub> of LTUC in males seems to decrease after 2000 but that of females appears elevated throughout the observation period. The CIR<sub>40–84</sub> of UTUC among females increased about 1.5 times that of males before 2000, which further climbed up to about 2 times.

It is interesting to know when the UC develops after initiation of dialysis. SIR of UTUC increased up to about more than 20–30 times in the first year after dialysis and then decreased slowly during the 12 years of observation [7]. The decreasing trend along calendar period could be expressed in the regression coefficient of Figure 3, especially among the females. However, while the male LTUC seems to show a decreasing trend expressed by the consistent negative signs of linear regression coefficients, those of females remain elevated in SIR until the period of 2003–8 to show a negative sign. We have also summarized the cumulative incidence rates of developing UC along time after dialysis in Figure 4.

Given such increased risks, we must consider the potential etiological factors. In general, risk factors that are reported to be associated with urothelial cancer include analgesics (phenacetin), herbal usage (aristolochic acid), heavy metals (arsenic), and tobacco smoking reported in international agency in research on cancer (IARC) [12]. Long-term use of phenacetin or NSAID is a potential risk factor for LTUC [13, 14]. Since IARC classified phenacetin as category 1 carcinogen for urothelial cancer in 1987, its compounds have been banned from Taiwan market since July of 1985 [15]. Moreover, patients with ESRD under dialysis are instructed to avoid taking NSAID (nonsteroidal anti-inflammatory drugs), which were illustrated by our data showing 99% of ESRD patients were prescribed NSAID for less than 500 pills within the two years before and after dialysis in both cancer and reference groups. Thus, phenacetin and/or NSAIDs did not seem to explain the above increased trend for both UTUC and LTUC. Since all patients with ESRD are recommended to avoid any food or medication suspected to contain metals that might accumulate in our body and only one out of 2708 cases of urothelial cancer after ESRD resided in the area of endemic arsenic poisoning (blackfoot disease), the etiological connection with arsenic seems unlikely. A preliminary study determining both arsenic and cadmium content in renal parenchyma tissue of three UTC cancers among patients with ESRD did not find any increase of these two metals in comparison with 26 samples without such cancers.

In several studies smoking is strongly related to LTUC and possibly UTUC in occurrence, recurrence, and progression [8, 12, 16]. Prevalence rate of tobacco consumption appears decreased from 60% down to below 40% in males, while that in females has remained about 5% or lower during the last 20 years according to data from the Department of
Figure 2: Prescription frequencies of aristolochic acid (AA) related and Xi-Xin Chinese herbal products (CHPs) in 90,477 patients with ESRD (end-stage renal disease), stratified by sex.

Figure 3: Estimated coefficients with 95% confidence intervals and standard errors (S.E.) for SIRs (standardized incidence ratios) linear trend during specified periods.

Health, Executive Yuan in a survey of general population [17]. Although the whole picture appears compatible with the trend of decreased LTUC in males (Figure 3), it cannot explain the increased SIR_{40−84} in females after age standardization. Moreover, almost all patients with ESRD were usually advised to quit or stay away from smoking by physicians. Since the time trends of UTUC for both genders in Table 2 were unrelated to the trends of cigarette consumption in Taiwan, we thus concluded that the increased UTUC in ESRD patients is probably not associated with smoking.

Aristolochic acid has been documented as nephrotoxic and carcinogenic and its related products or remedies are banned in many countries, including USA, UK, and Canada [18]. The above trends appear to correspond with the decreased consumption of several AA-containing products beginning in 1999 (Figure 2) and the ban on AA-containing CHPs in Taiwan on November 3 of 2003 (Figure 2) [8, 18]. The time trends of CIR_{40−84} of LTUC and UTUC in females appear to decline after calendar year 2000. This trend seems compatible with reduced consumption after 1998 and the
ban of aristolochic acid (AA) associated herbal products in 2003. After the year of 2000, the SIR$_{40-84}$ of UTUC appears to drop in both genders and the SIR$_{40-84}$ of LTUC declines in male significantly. These trends may be related to decreased consumption of cigarettes in males after 1990 and AA associated herbal products after 1998. Similar to what was reported in the AA related cancer in Belgium, the peak of LTUC usually appears as early as 3-4 years later than that of UTUC [19, 20]. Unfortunately, CHP that contains Xi-Xin is still available in market of Taiwan [21, 22], which might contain minute amount of AA after 25 times of concentration of the products and might still produce carcinogenic effect for patients with ESRD whose kidney is unable to excrete toxics [23]. As Xi-Xin is totally banned in America and Europe, AA related DNA adduct has been documented in cases of UTUC in Taiwan [24, 25]. We are currently conducting another study to estimate the doses of AA from prescribed Chinese herbal products and the association with occurrence of UC in dialysis patients, which may provide a more direct evidence for Taiwan to consider a similar action.

Limitations of this study include possible ecological fallacy and the lack of personal genetic and lifestyle information from the NHRI database, and details of tumor staging are not available in the NHIRD. We are also unable to quantify the exact consumption of analgesics and CHPs, as many of them are sold without prescription. Since the results of this study provide a preliminary inspection of the trend, they must be interpreted cautiously, and more studies are needed in the future to corroborate the proposed hypothesis.

5. Conclusions

Patients with ESRD requiring dialysis have increased after beginning of NHI system in Taiwan since 1995. Female patients diagnosed of ESRD were found to have 9–16 and 11–18 times of elevated risks of LTUC and UTUC, while those
of males were increased up to 4–8 and 7–14 times. The time trends of SIR$_{40–84}$ and CIR$_{40–84}$ of UTUC seem to synchronize with the increased prescription and consumption of AA associated herbs until 2000 [8, 26]. Further corroboration of this hypothesis may uncover the actual etiology and prevent more victims from urothelial cancer in Taiwan.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

This study was supported by a Grant from the Department of Health, Executive Yuan, Center of Excellence for Cancer Research (DOH100-TD-C-111-001) and another Grant from the National Health Research Institutes of Taiwan (intra-mural project EO-100-EO-PP04) for which the authors are grateful. They are also further indebted to the Bureau of National Health Insurance, the Department of Health, and the National Health Research Institutes for kindly providing them with the data for analysis in this study. The interpretation and conclusions contained herein are not, in any way, representative of those of the Bureau of National Health Insurance, the Department of Health, or the National Health Research Institutes.

**References**

[1] P. Maisonneuve, L. Agodoa, R. Gellert et al., “Cancer in patients on dialysis for end-stage renal disease: an international collaborative study,” *The Lancet*, vol. 354, no. 9173, pp. 93–99, 1999.
[2] T. Akiyama, M. Imanishi, H. Matsuda, T. Nishioka, S. Kunikata, and T. Kurita, “Difference among races in posttransplant malignancies: report from an oriental country,” *Transplantation Proceedings*, vol. 30, no. 5, pp. 2058–2059, 1998.
[3] J. H. Stewart, G. Buccianti, L. Agodoa et al., “Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand,” *Journal of the American Society of Nephrology*, vol. 14, no. 1, pp. 197–207, 2003.
[4] M. L. Aghaharkar, R. D. Cincir, Y.-F. Kuo, J. A. Daller, and V. B. Shahinian, “Risk of malignancy with long-term immunosuppression in renal transplant recipients,” *Kidney International*, vol. 66, no. 1, pp. 383–389, 2004.
[5] H.-W. Kuo, S.-S. Tsai, M.-M. Tiao, and C.-Y. Yang, “Epidemiological features of CKD in Taiwan,” *American Journal of Kidney Diseases*, vol. 49, no. 1, pp. 46–55, 2007.
[6] A. J. Collins, B. Kasiske, C. Herzog et al., “Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States,” *American Journal of Kidney Diseases*, vol. 45, no. 1, supplement 1, pp. A5–A7, 2005.
[7] H.-F. Lin, Y.-H. Li, C.-H. Wang, C.-L. Chou, D.-J. Kuo, and T.-C. Fang, “Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan,” *Nephrology Dialysis Transplantation*, vol. 27, no. 4, pp. 1585–1590, 2012.
[8] M. P. Zeegers, F. E. Tan, E. Dorant, and P. A. van den Brandt, “The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies,” *Cancer*, vol. 89, no. 3, pp. 630–639, 2000.
[9] M.-N. Lai, J.-N. Lai, P.-C. Chen, S.-C. Hsieh, F.-C. Hu, and J.-D. Wang, “Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study,” *American Journal of Kidney Diseases*, vol. 55, no. 3, pp. 507–518, 2010.
[10] M.-N. Lai, S.-M. Wang, P.-C. Chen, Y.-Y. Chen, and J.-D. Wang, “Population-based case-control study of chinese herbal products containing aristolochic acid and urinary tract cancer risk,” *Journal of the National Cancer Institute*, vol. 102, no. 3, pp. 179–186, 2010.
[11] B. Rosner, *Fundamentals of Biostatistics*, Cengage Learning, Boston, Mass, USA, 7th edition, 2010.
[12] *IARC Monographs List of Classifications by Cancer Site*, International Agency for Research on Cancer, Lyon, France, 1996, http://monographs.iarc.fr/ENG/Classification/Table4.pdf.
[13] J. Fortuny, M. Kogevinas, M. S. Zens et al., “Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study,” *BMC Urology*, vol. 7, article 13, 2007.
[14] J. A. Kaye, M. Wald Myers, and H. Jick, “Acetaminophen and the risk of renal and bladder cancer in the general practice research database,” *Epidemiology*, vol. 12, no. 6, pp. 690–694, 2001.
[15] J. M. Genkinger, I. DeVivo, M. J. Stampfer, E. Giovannucci, and D. S. Michaud, “Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study,” *InternationalJournal of Cancer*, vol. 120, no. 10, pp. 2221–2225, 2007.
[16] A. G. van der Heijden and J. A. Witjes, “Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer,” *European Urology, Supplements*, vol. 8, no. 7, pp. 556–562, 2009.
[17] *Adult Smoking Behavior Surveillance System*, ASBS, 2013, http://tobacco.hpa.gov.tw/Show.aspx?MenuId=581.
[18] D. A. Kessler, “Cancer and herbs,” *The New England Journal of Medicine*, vol. 342, no. 23, pp. 1742–1743, 2000.
[19] J. L. Nortier, M.-C. M. Martinez, H. H. Schmeiser et al., “Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi),” *The New England Journal of Medicine*, vol. 342, no. 23, pp. 1686–1692, 2000.
[20] A. Lemy, K. M. Wissing, S. Rorive et al., “Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up,” *American Journal of Kidney Diseases*, vol. 51, no. 3, pp. 471–477, 2008.
[21] S.-C. Hsieh, I.-H. Lin, W.-L. Tseng, C.-H. Lee, and J.-D. Wang, “Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003,” *Chinese Medicine*, vol. 3, article 13, 2008.
[22] S.-C. Hsieh, J.-N. Lai, C.-F. Lee, F.-C. Hu, W.-L. Tseng, and J.-D. Wang, “The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database,” *Pharmacoepidemiology and Drug Safety*, vol. 17, no. 6, pp. 609–619, 2008.
[23] S.-C. Hsieh, J.-N. Lai, P.-C. Chen, C.-C. Chen, H.-J. Chen, and J.-D. Wang, “Is Duhuo Jisheng Tang containing Xixin safe? A four-week safety study,” *Chinese Medicine*, vol. 5, no. 1, article 6, 2010.
[24] C. H. Chen, K. G. Dickman, M. Moriya et al., “Aristolochic acid-associated urothelial cancer in Taiwan,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 21, pp. 8241–8246, 2012.

[25] M. L. Hoang, C. Chen, V. S. Sidorenko et al., “Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing,” Science Translational Medicine, vol. 5, no. 197, p. 10, 2013.

[26] D. A. Kessler, “Cancer and herbs,” The New England Journal of Medicine, vol. 342, no. 23, pp. 1742–1743, 2000.